Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CELU vs FBRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FBRX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–0 Matrix Metrics)
FBRX Overall Winner
6-Pillar Tally: CELU 2 – 3 FBRX (1 Tie)
Matrix Metrics: CELU 0 – 8 FBRX
As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CELU carries a Unified Composite Score of 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin), whereas FBRX carries 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CELU vs FBRX
CELU
Celularity Inc. Class A Common Stock
$0.46
-1.05% 1D
Market Cap
$15.2M
TTM Revenue
$19M
Forward P/E
N/M
Beta / 30D Vol
2.01β · 135% Vol
Unified Composite Score
42.9
HOLD
Tech 25.0
Fund 48.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
FBRX
Head-to-Head Winner
Forte Biosciences, Inc. Common Stock
$76.99
+0.03% 1D
Market Cap
$1.6B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.09β · 3% Vol
Unified Composite Score
52.7
HOLD
Tech 49.0
Fund 51.0
Flow 62.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (CELU 2 – 3 FBRX)
1. Valuation Multiples
CELU
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
2.7x
N/M
2. Growth & Scale
FBRX
Revenue Growth (YoY)
-5.3%
+0.0%
Earnings Growth (YoY)
-61.3%
+0.0%
TTM Revenue (USD)
$19M
N/A
Market Cap
$15.2M
$1.6B
3. Profitability & Quality
FBRX
Gross Margin
19.2%
N/A
Operating Margin
-254.0%
0.0%
Net Profit Margin
-245.7%
0.0%
Return on Equity (ROE)
-6367.2%
-62.3%
4. Balance Sheet & Cash Flow
CELU
Cash Generation (TTM)
-$8.9M
-$72M
Cash Flow Margin
-47.8%
N/A
Net Cash / Leverage
$35M Net Debt
$7.52 Book/Sh · -62.3% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FBRX
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
116.6% (50th %ile)
11.1% (3rd %ile)
Put/Call OI Skew
3.60x (Put-Skewed)
0.77x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CELU (0) vs FBRX (8)| Institutional Metric | CELU | FBRX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $15.2M | $1.6B | FBRX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -5.3% | +0.0% | FBRX | |
| Operating Margin (TTM) | -254.0% | 0.0% | FBRX | |
| Net Profit Margin | -245.7% | 0.0% | FBRX | |
| Return on Equity (ROE) | -6367.2% | -62.3% | FBRX | |
| 52-Week Range Position | 2% ($0–$3) | 100% ($10–$77) | FBRX | |
| Beta / 30D Volatility | 2.01β · 135% Vol | 1.09β · 3% Vol | FBRX | |
| Unified Institutional Score | 42.9 / 100 (HOLD) | 52.7 / 100 (HOLD) | FBRX | |
| Trailing 12M Revenue (USD) | $19M | N/A | Scale | |
| Gross Profit Margin (TTM) | 19.2% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 2.7x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$8.9M ($35M Net Debt) | -$72M ($7.52 Book/Sh · -62.3% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CELU +15.39 pp
3M Horizon
FBRX +262.38 pp
6M Horizon
FBRX +200.28 pp
1Y Horizon
FBRX +359.4 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CELU Revenue | FBRX Revenue | CELU Op. Margin | FBRX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $20M | N/A | -254.2% | FBRX |
| FY2019 | N/A | $0M | N/A | -11288.9% | FBRX |
| FY2020 | $10M | N/A | -1064.0% | N/A | CELU |
| FY2021 | $20M | N/A | -511.2% | N/A | CELU |
| FY2022 | $20M | N/A | -142.4% | N/A | CELU |
| FY2023 | $20M | N/A | -844.4% | N/A | CELU |
| FY2024 | $50M | N/A | -70.7% | N/A | CELU |
| FY2025 | $30M | N/A | -230.9% | N/A | CELU |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CELU
BREAKDOWN
Current IV
116.6%
IV Percentile
50th %ile
Put/Call OI Skew
3.60x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
FBRX
UNCLASSIFIED
Current IV
11.1%
IV Percentile
3rd %ile
Put/Call OI Skew
0.77x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CELU Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
FBRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CELU vs FBRX Key Questions & Quantitative Answers
As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CELU carries a Unified Composite Score of 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin), whereas FBRX carries 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FBRX leads the Growth & Scale pillar: CELU posts -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin), compared with FBRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CELU cumulative revenue shifted +200.0% while FBRX shifted N/A. In operating R&D and SG&A reinvestment, CELU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FBRX.
CELU screens cheaper on headline valuation multiples. CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin), whereas FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELU (-6367.2% ROE) versus FBRX (-62.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk). By comparison, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
FBRX vs CELU · Reverse Pair
FBRX vs KRSA
· Sector Peer
FBRX vs DMRA
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal